Cochlear (ASX:COH) sees FDA approval for Remote Check

Company News

by Rachael Jones

Implantable hearing solutions company Cochlear (ASX:COH) has obtained US Food and Drug Administration (FDA) approval for its Remote Check solution.

Remote Check is the first telehealth patient assessment tool, an at-home testing tool that allows people with a Cochlear™ Nucleus® 7 Sound Processor to complete a series of hearing checks from an app.

Cochlear will begin a controlled release of Remote Check in the US and intends to accelerate the release in Canada, the United Kingdom, and select countries in Western Europe.

Following increased demand for remote care due to the COVID-19 pandemic, the FDA expedited its approval.

Shares in Cochlear (ASX:COH) are trading 0.87 per cent lower at $181.59.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.